Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130923 · ClinicalTrials.gov registry record · Phase 4
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT00130923 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 95 participants.
The verdict
NCT00130923, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
Interventions
- DRUG Risperidone Long Acting
- DRUG oral risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130923
The ClinicalTrials.gov registry entry for NCT00130923 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone Long Acting is the first listed.
NCT00130923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130923 about?
NCT00130923 is a clinical study titled "Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder". The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
What is the current status of trial NCT00130923?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2005-09. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00130923?
The interventions under investigation include: Risperidone Long Acting (DRUG), oral risperidone (DRUG).
Who is sponsoring clinical trial NCT00130923?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.